183556-68-5Relevant academic research and scientific papers
Preparation of labeled bis-amino acid hydroxyethylamino sulfonamide HIV protease inhibitors
Cao, Kai,Chen, Shiang-Yuan,Prakash, Shimoga R.
, p. 353 - 363 (2007/10/03)
Preparation of radiolabeled sulfonamide HIV protease inhibitors, DMP852 and DMP853 is described. The C-14 labeling of DMP852 was accomplished by acylation of the intermediate amine with [1-14C]-chloroacetic anhydride followed by the treatment of the chloroacetyl derivative with methylamine. Due to the rapid loss of the methylglycine moiety during metabolism studies, a route that involved an oxidation-reduction sequence was employed to prepare tritium labeled DMP852. Similar methodology was utilized to prepare tritium labeled DMP853. Copyright
Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
-
Page column 74, (2008/06/13)
Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.
Retroviral protease inhibitor combinations
-
, (2008/06/13)
The present invention is directed to a method for the treatment of mammalian retrovirus infections, such as HIV, using combinations of retroviral protease inhibitors which are effective in preventing the replication of the retroviruses in vitro or in vivo
Bis-amino acid hydroxyethlamino sulfonamide retroviral protease inhibitors
-
, (2008/06/13)
PCT No. PCT/US96/02685 Sec. 371 Date Jan. 21, 1997 Sec. 102(e) Date Jan. 21, 1997 PCT Filed Mar. 7, 1996 PCT Pub. No. WO96/28464 PCT Pub. Date Sep. 19, 1996Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.
Bis-amino acid hydroxyethylamino sulfonamide retroviral protease inhibitors
-
, (2008/06/13)
Selected bis-amino acid hydroxyethylamino sulfonamide compounds are effective as retroviral protease inhibitors, and in particular as inhibitors of HIV protease. The present invention relates to such retroviral protease inhibitors and, more particularly, relates to selected novel compounds, composition and method for inhibiting retroviral proteases, such as human immunodeficiency virus (HIV) protease, prophylactically preventing retroviral infection or the spread of a retrovirus, and treatment of a retroviral infection.
